AEON Biopharma, Inc. (AEON) - Total Liabilities
Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has total liabilities worth $28.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AEON Biopharma, Inc. (AEON) cash flow conversion to assess how effectively this company generates cash.
AEON Biopharma, Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how AEON Biopharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check AEON Biopharma, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
AEON Biopharma, Inc. Competitors by Total Liabilities
The table below lists competitors of AEON Biopharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brimstone Investment Corporation Ltd
JSE:BRT
|
South Africa | ZAC2.05 Billion |
|
Volcano Bhd
KLSE:0232
|
Malaysia | RM52.09 Million |
|
Finsbury Growth & Income Trust
LSE:FGT
|
UK | GBX33.77 Million |
|
Sarama Resources Ltd
AU:SRR
|
Australia | AU$1.62 Million |
|
ECSTELECOM Co. Ltd
KQ:067010
|
Korea | ₩29.23 Billion |
|
Teera-Mongkol Industry Public Company Limited
BK:TMI
|
Thailand | ฿451.73 Million |
|
Inotiv Inc
NASDAQ:NOTV
|
USA | $625.31 Million |
|
Pertama Digital Berhad
KLSE:8532
|
Malaysia | RM190.99 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down AEON Biopharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AEON Biopharma, Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AEON Biopharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual total liabilities of AEON Biopharma, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $31.71 Million | -80.17% |
| 2023-12-31 | $159.89 Million | -43.14% |
| 2022-12-31 | $281.19 Million | +22.12% |
| 2021-12-31 | $230.26 Million | +2.59% |
| 2020-12-31 | $224.45 Million | +24.54% |
| 2019-12-31 | $180.22 Million | -- |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more